Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$2.69
+1.1%
$3.04
$2.56
$6.66
$163.18M0.571.12 million shs899,314 shs
Equillium, Inc. stock logo
EQ
Equillium
$2.69
-2.5%
$2.74
$0.36
$3.54
$174.51M1.771.01 million shs302,284 shs
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
$1.76
-0.8%
$1.82
$1.17
$2.63
$166.71M0.327,719 shs4,372 shs
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
$0.70
-2.1%
$0.95
$0.51
$1.55
$40.01M1.59315,738 shs207,614 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-0.75%0.00%-7.32%-18.90%-47.33%
Equillium, Inc. stock logo
EQ
Equillium
+4.94%+5.34%-3.50%+27.19%+605.88%
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
+1.14%-1.11%-1.66%+29.93%-5.57%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-5.86%-4.09%-23.98%-22.91%-37.78%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$2.69
+1.1%
$3.04
$2.56
$6.66
$163.18M0.571.12 million shs899,314 shs
Equillium, Inc. stock logo
EQ
Equillium
$2.69
-2.5%
$2.74
$0.36
$3.54
$174.51M1.771.01 million shs302,284 shs
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
$1.76
-0.8%
$1.82
$1.17
$2.63
$166.71M0.327,719 shs4,372 shs
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
$0.70
-2.1%
$0.95
$0.51
$1.55
$40.01M1.59315,738 shs207,614 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-0.75%0.00%-7.32%-18.90%-47.33%
Equillium, Inc. stock logo
EQ
Equillium
+4.94%+5.34%-3.50%+27.19%+605.88%
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
+1.14%-1.11%-1.66%+29.93%-5.57%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-5.86%-4.09%-23.98%-22.91%-37.78%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
2.00
HoldN/AN/A
Equillium, Inc. stock logo
EQ
Equillium
2.82
Moderate Buy$7.57181.47% Upside
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
2.50
Moderate Buy$5.00184.09% Upside
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2.33
Hold$9.001,184.80% Upside

Current Analyst Ratings Breakdown

Latest PDSB, IPHA, EQ, and ACB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/21/2026
Equillium, Inc. stock logo
EQ
Equillium
UpgradeStrong-Buy
7/17/2026
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
Reiterated RatingSell (E+)
7/13/2026
Equillium, Inc. stock logo
EQ
Equillium
Initiated CoverageOverweight
7/13/2026
Equillium, Inc. stock logo
EQ
Equillium
DowngradeHoldStrong Sell
6/26/2026
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
UpgradeSell (E+)Sell (D-)
6/24/2026
Equillium, Inc. stock logo
EQ
Equillium
Reiterated RatingSell (D-)
6/16/2026
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
UpgradeSell (D-)Sell (D)
6/1/2026
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
DowngradeSell (D-)Sell (E+)
5/28/2026
Equillium, Inc. stock logo
EQ
Equillium
Reiterated RatingStrong-Buy$7.00
5/28/2026
Equillium, Inc. stock logo
EQ
Equillium
Set Price Target$5.00
5/28/2026
Equillium, Inc. stock logo
EQ
Equillium
Reiterated RatingBuy$12.00
(Data available from 7/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$247.82M0.67$0.70 per share3.82$6.27 per share0.43
Equillium, Inc. stock logo
EQ
Equillium
$41.10M4.14N/AN/A$0.47 per share5.72
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
$10.19M16.22N/AN/A($0.26) per share-6.77
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
N/AN/AN/AN/A$0.18 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$88.13M-$1.56N/AN/AN/A-33.57%0.10%0.07%8/5/2026 (Estimated)
Equillium, Inc. stock logo
EQ
Equillium
-$22.40M-$0.32N/AN/AN/AN/A-61.43%-53.72%8/13/2026 (Estimated)
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
-$55.64MN/AN/AN/AN/AN/AN/AN/A9/17/2026 (Estimated)
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$34.50M-$0.67N/AN/AN/AN/A-346.02%-102.36%8/12/2026 (Estimated)

Latest PDSB, IPHA, EQ, and ACB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Equillium, Inc. stock logo
EQ
Equillium
-$0.05N/AN/AN/AN/AN/A
8/12/2026Q2 2026
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$0.13N/AN/AN/AN/AN/A
8/5/2026Q1 2027
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$0.13N/AN/AN/A$48.52 millionN/A
6/11/2026Q4 2026
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$0.07$0.07+$0.14$0.86$54.42 million$60.98 million
5/13/2026Q1 2026
Equillium, Inc. stock logo
EQ
Equillium
-$0.04-$0.06-$0.02-$0.06N/AN/A
5/13/2026Q1 2026
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$0.15-$0.13+$0.02-$0.13N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Equillium, Inc. stock logo
EQ
Equillium
N/AN/AN/AN/AN/A
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
N/AN/AN/AN/AN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.04
5.94
3.32
Equillium, Inc. stock logo
EQ
Equillium
N/A
18.62
18.62
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
N/A
1.27
1.27
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2.73
2.26
2.26

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Equillium, Inc. stock logo
EQ
Equillium
27.05%
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
0.16%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
26.84%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Equillium, Inc. stock logo
EQ
Equillium
17.84%
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
31.89%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
8.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,02861.34 million61.34 millionOptionable
Equillium, Inc. stock logo
EQ
Equillium
4063.23 million51.95 millionNot Optionable
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
22093.92 million63.97 millionNot Optionable
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2055.92 million51.23 millionOptionable

Recent News About These Companies

PDS Biotechnology Corp.
PDS Biotechnology: Q4 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$2.69 +0.03 (+1.13%)
Closing price 04:00 PM Eastern
Extended Trading
$2.67 -0.02 (-0.74%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Equillium stock logo

Equillium NASDAQ:EQ

$2.69 -0.07 (-2.54%)
Closing price 04:00 PM Eastern
Extended Trading
$2.68 0.00 (-0.19%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Innate Pharma stock logo

Innate Pharma NASDAQ:IPHA

$1.76 -0.02 (-0.85%)
Closing price 04:00 PM Eastern
Extended Trading
$1.77 +0.01 (+0.57%)
As of 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

PDS Biotechnology stock logo

PDS Biotechnology NASDAQ:PDSB

$0.70 -0.02 (-2.10%)
Closing price 04:00 PM Eastern
Extended Trading
$0.71 +0.01 (+1.07%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.